Q3 Results 2026

Reckitt posts solid Q3 growth, but North America lags amid supply constraints.

What the company is saying

Reckitt Benckiser Group PLC reports 3.3% like-for-like net revenue growth in Q3 2026 across Core Reckitt, with performance framed as resilient despite a challenging consumer environment. The company highlights broad-based gains, especially in Emerging Markets, which delivered 8.0% LFL growth (9.8% excluding Russia Hygiene), and emphasizes a return to growth in Europe (+0.8% LFL). North America is acknowledged as underperforming, with a 1.3% LFL decline due to temporary manufacturing constraints affecting Lysol, though management expects a Q4 rebound as capacity upgrades are completed. CEO Kris Licht attributes the North American shortfall to these operational issues and signals confidence in resolving them. The narrative stresses ongoing investment—specifically a multi-year, up to $600m commitment to U.S. innovation and supply resilience—and continued brand innovation, with recent launches such as Mucinex 12HR Cold & Fever and Dettol Activ Botany. The company also spotlights a £500m share buyback (with £90m completed by 23 October 2026), and progress on the Russia Hygiene divestment, expected to close in H2 2026. Updated FY 2026 guidance is for 3.5% to 4.5% Core Reckitt LFL net revenue growth, with high-single-digit gains in Emerging Markets and low-single-digit growth in Mead Johnson Nutrition.

What the data suggests

The disclosed figures show Core Reckitt Q3 net revenue of £2,690m (+3.3% LFL), with Emerging Markets contributing £1,174m (+8.0% LFL), Europe £867m (+0.8% LFL), and North America £649m (-1.3% LFL). Year-to-date, Core Reckitt net revenue stands at £7,800m (+2.9% LFL), while the group total is £9,773m (+2.8% LFL, but -7.7% IFRS due to the Essential Home divestment). Volume and price/mix dynamics vary: Europe saw a -3.2% volume decline offset by +4.0% price/mix, North America had +0.7% volume but -2.0% price/mix, and Emerging Markets combined +2.3% volume with +5.7% price/mix in Q3. Category growth is led by Germ Protection (+6.0%) and Intimate Wellness (+6.4%), while Household Care declined overall due to Russia Hygiene. The $600m North American investment is disclosed but not yet reflected in results. The £500m buyback is underway, with £90m executed. Adjusted operating profit margin for FY 2026 is guided at 24.9%–25.6%, and adjusted net finance expense at £250m–£270m. The evidence supports the headline growth claims, but brand-level and country-specific outperformance is asserted without supporting numbers. North America's underperformance is directly linked to manufacturing constraints, not demand weakness.

Analysis

The announcement presents a positive tone, highlighting like-for-like net revenue growth across most regions and segments, with detailed numerical support for group and regional performance. However, a significant portion of the key claims are forward-looking, including updated FY 2026 guidance, expectations for Emerging Markets and Mead Johnson Nutrition, and medium-term growth ambitions. The multi-year $600m North American investment is capital intensive, but its benefits are not immediate and are described in broad, aspirational terms. While adjusted operating profit margin guidance is provided, actual profitability figures for the quarter are not disclosed, limiting the ability to assess whether revenue growth is translating into value. Several qualitative claims about brand and country-specific outperformance lack supporting data, inflating the narrative beyond what is evidenced. Overall, the data supports a weak_positive signal, with moderate hype due to the mix of realised and aspirational claims.

Risk flags

• ●North America faces operational risk from manufacturing constraints, which directly limited Q3 revenue and could persist if upgrades are delayed; the company expects resolution in Q4, but execution is critical.
• ●The Essential Home divestment creates a structural headwind, reflected in a -7.7% IFRS revenue decline year-to-date, and introduces stranded cost risk, though management claims mitigation via the Fuel for Growth programme.
• ●Emerging Markets growth is strong but exposed to macroeconomic volatility, regulatory changes (e.g., VAT in China, GST in India), and competitive pressures, as seen in VMS headwinds from local competitors in China.
• ●Brand and country-level performance claims lack granular disclosure, making it difficult to independently verify the breadth and sustainability of outperformance, especially for key brands and markets.
• ●The $600m North American investment is capital intensive, and while aimed at innovation and supply resilience, the return on this outlay is not yet visible in financial results and carries execution risk.

Bottom line

Reckitt's Q3 2026 update demonstrates solid like-for-like revenue growth in most regions, with Emerging Markets and Europe performing well, but North America underdelivering due to temporary supply constraints on Lysol. The company's narrative is credible on headline numbers, but detailed brand and market claims are not fully substantiated by disclosed data. The £500m buyback and $600m North American investment signal confidence and a focus on long-term growth, but the latter's payoff will take time to materialize. Execution on manufacturing upgrades and completion of the Russia Hygiene divestment are near-term catalysts. Investors should watch for Q4 North American recovery and evidence that capital investment translates into sustained margin and revenue gains. The most important takeaway is that while Reckitt is delivering growth in a tough environment, operational execution—especially in North America—remains the key variable for near-term upside.

Announcement summary

(LSE:RKT) Reckitt Benckiser Group PLC reported Q3 2026 results, delivering 3.3% like-for-like (LFL) net revenue growth in Q3 across Core Reckitt, and 3.9% excluding Russia Hygiene. Emerging Markets achieved 8.0% LFL net revenue growth in Q3, or 9.8% excluding Russia Hygiene, with all regions in growth and double-digit growth in Indonesia, Vietnam, South Africa, and Colombia. Europe returned to growth with Q3 LFL net revenue up 0.8%, led by strong performances from Gaviscon, Vanish, and Veet, and a return to growth for Finish, Durex, and Harpic. North America Q3 LFL net revenue declined 1.3% to £649m, impacted by temporary manufacturing constraints affecting Lysol supply, though volume grew 0.7%. Core Reckitt Q3 net revenue was £2,690m (+3.3% LFL), and YTD net revenue was £7,800m (+2.9% LFL). Mead Johnson Nutrition delivered 2.7% LFL net revenue growth in Q3, driven by premiumisation and innovation in Latin America and South East Asia. Total Group Q3 net revenue was £3,362m (+3.2% LFL, -6.9% IFRS), and YTD was £9,773m (+2.8% LFL, -7.7% IFRS), with IFRS declines reflecting the prior year’s Essential Home contribution. The company announced a multi-year investment of up to $600m in September to accelerate U.S.-based innovation, expand Healthcare access, and strengthen supply resilience in North America. A £500m share buyback programme commenced on 5 August 2026, with £90m completed as of 23 October 2026. The company expects to complete the Russia Hygiene divestment during H2 2026. For FY 2026, Core Reckitt LFL net revenue growth guidance is now 3.5% to 4.5%, with Emerging Markets expected to deliver high-single-digit growth and Mead Johnson Nutrition low-single-digit LFL growth. Core Reckitt + MJN adjusted operating profit (AOP) margin for FY 2026 is expected in the range of 24.9% to 25.6%, with H2 margin stronger than H1 (23.6%). FY 2026 adjusted net finance expense is expected to be £250m to £270m (2025: £346m), and for 2027, £390m to £410m. The adjusted effective tax rate for FY 2026 is expected to be 26% to 27% (2025: 24.7%), with a longer-term rate around 27%. Capital expenditure as a percentage of net revenue is expected to be around 4% (2025: 4.2%). The company reiterates medium-term guidance for Core Reckitt to deliver 4% to 5% LFL net revenue growth and annual EPS growth. Leading brands such as Dettol, Durex, Gaviscon, Finish, Vanish, and Veet showed strong or improving performance across key markets. The company continues to invest in innovation and brand capabilities, with recent launches including Mucinex 12HR Cold & Fever, Dettol Activ Botany, and Vanish Turbo. The next Focus On event will be hosted from the North American headquarters in New Jersey on 19 November.

Disagree with this article?